Haematopoietic cell transplantation with and without sorafenib maintenance for patients with <i> <scp>FLT</scp> 3 </i> ‐ <scp>ITD</scp> acute myeloid leukaemia in first complete remission
Andrew M. Brunner(Harvard University), Yi‐Bin Chen(Massachusetts General Hospital), Corey Cutler(Harvard University), John Koreth(Otsuka (Japan)), Vincent T. Ho(Dana-Farber Cancer Institute), Thomas R. Spitzer(Harvard University), Karen K. Ballen(University of Virginia Health System), Martha Wadleigh(Dana-Farber Cancer Institute), Joseph H. Antin(Dana-Farber Cancer Institute), Sarah Nikiforow(Otsuka (Japan)), Robert J. Soiffer(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Areej El‐Jawahri(Massachusetts General Hospital), Kerry Collier(Massachusetts General Hospital), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Shuli Li(Unknown), Steven L. McAfee(Harvard University), Bimalangshu R. Dey(Harvard University), Christine Connolly(Massachusetts General Hospital), Amir T. Fathi(University of Southern California)
Cited by 174
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k